The infographic contains a selection of data points and observations from this estrogen therapeutics market report.
The global estrogen therapeutics market is expected to expand at a CAGR of more than 2% during the forecast period
Estrogen therapeutics market growth is expected to accelerate over the next five years, driven by countries around the world. While the Americas will drive the largest growth of almost 50%, EMEA and APAC are also expected to make significant contributions of around 25% each to the incremental growth in the forecast period. The Americas held the largest market share of over 56% in 2017, followed by EMEA with around 26% and APAC accounting for almost 18%. Estrogen plays a vital role in the development of reproductive functions and neurodevelopment in females which has lead to increased R&D of estrogen signaling and alteration in the level of estrogen receptors as a therapeutic target for combating and treating neurodevelopment disorders. Technavio's estrogen therapeutics market analysis reveals promising markets around the world.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Estrogen gels are the leading segment in the market with a revenue share of over 35%
The leading segment in the market is that of estrogen gels, followed by oral medication with a share of almost 32%, suppositories accounting for around 20%, and skin patches with a share of about 19%. Estrogen therapy refers to the estrogen-based treatment of medical conditions using drugs or other methods. Increasing awareness about the benefit of estrogen therapy is likely to drive the demand for the market over the forecast period. However, the market share of skin patches is expected to decline to under 13% by the end of the forecast period. Additionally, the increased benefits of estrogen therapy coupled with growing rates of successful treatment absorption will drive the estrogen therapeutics market growth during the period of forecast.
Get more value with Technavio's subscription platform! Gain easy access to all Technavio's reports, along with on-demand services. Start your 14-day FREE trial
Abbott, Bayer, and Novartis are among leading vendors in the estrogen therapeutics market
As the market continues to flourish, it is growing moderately concentrated with the existence of many well-established large players and regional vendors. The awareness about the negative impact of menopausal symptoms on the quality of life varies widely among different societies and countries. In developed countries, the knowledge regarding occurrence and impact of menopausal symptoms and benefits of estrogen therapy is widespread due to public literacy and health programs initiated by the government. However, a large section of the population in the developing economies possess a lack of knowledge and awareness about estrogen therapy. But the growing awareness about the benefits of estrogen therapy and hormone replacement therapy (HRT) is these emerging economies are forecasted to drive the growth of the market during the period of forecast. Many international and regional vendors are vying for their share of the estrogen therapeutics market, and players must differentiate themselves to gain vital traction over their competitors.
This report offers a complete analysis of several estrogen therapeutics companies, including:
- Abbott
- Bayer
- Novartis
- Novo Nordisk
- Pfizer
Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch